Last $8.00 USD
Change Today -0.06 / -0.74%
Volume 323.2K
SUPN On Other Exchanges
Symbol
Exchange
NASDAQ GM
Frankfurt
As of 8:10 PM 04/24/14 All times are local (Market data is delayed by at least 15 minutes).

supernus pharmaceuticals inc (SUPN) Snapshot

Open
$8.14
Previous Close
$8.06
Day High
$8.14
Day Low
$7.73
52 Week High
03/5/14 - $10.55
52 Week Low
04/25/13 - $4.45
Market Cap
336.1M
Average Volume 10 Days
406.4K
EPS TTM
$-2.21
Shares Outstanding
42.0M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for SUPERNUS PHARMACEUTICALS INC (SUPN)

Related News

No related news articles were found.

supernus pharmaceuticals inc (SUPN) Related Businessweek News

No Related Businessweek News Found

supernus pharmaceuticals inc (SUPN) Details

Supernus Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system diseases in the United States. Its products include Oxtellar XR and Trokendi XR, which are neurology products used for the treatment of epilepsy; SPN-810, a molindone hydrochloride that has completed Phase IIb clinical trials for the treatment of impulsive aggression in patients with attention deficit hyperactivity disorder (ADHD); and SPN-812, which has completed Phase IIa clinical trials for the treatment of ADHD. The company is also developing SPN-809 as a once-daily product candidate for the treatment of depression. It markets its products through wholesalers and pharmaceutical distributors. Supernus Pharmaceuticals, Inc. was founded in 2005 and is based in Rockville, Maryland.

235 Employees
Last Reported Date: 03/21/14
Founded in 2005

supernus pharmaceuticals inc (SUPN) Top Compensated Officers

Founder, Chief Executive Officer, President, ...
Total Annual Compensation: $462.9K
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $308.9K
Chief Scientific Officer and Senior Vice Pres...
Total Annual Compensation: $314.8K
Chief Medical Officer and Executive Vice Pres...
Total Annual Compensation: $156.2K
Compensation as of Fiscal Year 2013.

supernus pharmaceuticals inc (SUPN) Key Developments

Supernus Pharmaceuticals, Inc. Reports Unaudited Consolidated Earnings Results for the Fourth Quarter and Year Ended Dec. 31, 2013; Provides Earnings Guidance for the Year 2014

Supernus Pharmaceuticals, Inc. reported unaudited consolidated earnings results for the fourth quarter and year ended Dec. 31, 2013. For the quarter, the company reported total revenue of $10,334,000 compared to $1,089,000 a year ago. Operating loss was $11,357,000 compared to $12,743,000 a year ago. Net loss attributable to common stockholders was $22,406,000 or $0.65 per basic and diluted share compared to $13,512,000 or $0.51 per basic and diluted share a year ago. Adjusted net loss was $13,356,000. For the year, the company reported total revenue of $12,019,000 compared to $1,480,000 a year ago. Operating loss was $61,920,000 compared to $42,169,000 a year ago. Net loss attributable to common stockholders was $92,273,000 or $2.90 per basic and diluted share compared to $47,427,000 or $2.72 per basic and diluted share a year ago. The higher loss in 2013 reflects increased expenses associated with the launch and commercialization activities of Oxtellar XR and Trokendi XR. Adjusted net loss was $69,369,000. Non-GAAP net loss for full year 2013 was $69.4 million. For the full year 2014, cash burn is forecasted to range from $35 million to $45 million, with a year-end cash balance projected to range from $35 million to $45 million. Total revenue for calendar year 2014 is expected to range from $75 million to $85 million. The company continues to expect product gross margins to exceed 90%.

Supernus Pharmaceuticals, Inc., Q4 2013 Earnings Call, Mar 13, 2014

Supernus Pharmaceuticals, Inc., Q4 2013 Earnings Call, Mar 13, 2014

Supernus Pharmaceuticals, Inc. to Report Q4, 2013 Results on Mar 12, 2014

Supernus Pharmaceuticals, Inc. announced that they will report Q4, 2013 results After-Market on Mar 12, 2014

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
SUPN:US $8.00 USD -0.06

SUPN Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for SUPN.
View Industry Companies
 

Industry Analysis

SUPN

Industry Average

Valuation SUPN Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 23.2x
Price/Book 9.6x
Price/Cash Flow NM Not Meaningful
TEV/Sales 18.5x
 | 

Post a JobJobs

View all jobs

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact SUPERNUS PHARMACEUTICALS INC, please visit www.supernus.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.